Knight K R, Dvir E, Kawabata H, Coe S A, Macleod A M, O'Brien B M
Microsurgery Research Centre, St Vincent's Hospital, Melbourne, Australia.
Br J Plast Surg. 1989 Nov;42(6):675-81. doi: 10.1016/0007-1226(89)90080-5.
Rabbit epigastric free flaps were subjected to ischaemia at 25 degrees C for 24 hours. At the time of revascularisation the flaps were infused intra-arterially with one of the following: Hanks balanced salt solution (control), the high energy phosphates PEP/ATP, the thromboxane synthetase inhibitor dazoxiben hydrochloride, the free radical scavenger SOD and a combination of all these agents (treated groups). Control ischaemic flap survival at post-ischaemia day 7 was 23.5%, while the other treatments resulted in improved flap survival of 43.5% (p less than 0.025), 23.5% (not significant), 38.6% (p less than 0.05) and 35.7% (p less than 0.05) respectively. None of these agents improved post-ischaemic blood flow significantly. These results would support the use of PEP/ATP or SOD in the clinical treatment of failing ischaemic skin flaps but do not support the use of dazoxiben hydrochloride.
将兔腹壁游离皮瓣在25℃下进行24小时缺血处理。在血管再通时，皮瓣通过动脉内注入以下物质之一：汉克斯平衡盐溶液（对照组）、高能磷酸盐PEP/ATP、血栓素合成酶抑制剂盐酸达唑氧苯、自由基清除剂超氧化物歧化酶以及所有这些药物的组合（治疗组）。缺血后第7天，对照组缺血皮瓣存活率为23.5%，而其他治疗方法使皮瓣存活率分别提高到43.5%（p<0.025）、23.5%（无显著差异）、38.6%（p<0.05）和35.7%（p<0.05）。这些药物均未显著改善缺血后的血流。这些结果支持在临床治疗缺血性皮瓣坏死时使用PEP/ATP或超氧化物歧化酶，但不支持使用盐酸达唑氧苯。
